<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Cell. Author manuscript; available PMC 2012 August 17. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Cell. 2012 February 17; 148(4): 639&#226;&#8364;&#8220;650. doi:10.1016/j.cell.2011.12.033. <br />  <br />  <br />  <br />                            TAK1 (MAP3K7) inhibition promotes apoptosis KRAS- <br />                            dependent colon cancers <br />                            Anurag Singh1,3, Michael F. Sweeney1, Min Yu1, Alexa Burger1, Patricia Greninger1, Cyril <br />                            Benes1, Daniel  Haber1,2,*, Jeff Settleman1,4,* <br />  <br />                            1MassachusettsGeneral Hospital Cancer Center Harvard Medical School, Charlestown, MA <br />                            02129 2Howard Hughes Medical Institute, Chevy Chase, Maryland <br />  <br />                            Summary <br />                                  Colon cancers frequently harbor KRAS mutations, subset KRAS-mutant colon <br />                                  cancer cell lines dependent KRAS signaling survival. screen kinases NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                  promote survival KRAS-dependent colon cancer cells, TAK1 kinase <br />                                  (MAP3K7) required tumor cell viability. induction apoptosis RNAi-mediated <br />                                  depletion pharmacologic inhibition TAK1 linked suppression hyperactivated Wnt <br />                                  signaling, evident endogenous genetically reconstituted cells. APC-mutant/KRAS- <br />                                  dependent cells, KRAS stimulates BMP-7 secretion BMP signaling, leading TAK1 <br />                                  activation enhancement Wnt-dependent transcription. vitro-derived &#226;&#8364;&#339;TAK1- <br />                                  dependency signature&#226;&#8364;? enriched primary human colon cancers mutations APC <br />                                  KRAS, suggesting potential clinical utility stratifying patient populations.                                   findings identify TAK1 inhibition potential therapeutic strategy treatment-refractory <br />                                  subset colon cancers exhibiting aberrant KRAS Wnt pathway activation. <br />  <br />  <br />                            Introduction <br />                                              Targeted cancer therapies exploited specific mutations drive survival signals                                              subsets tumors, leading successful genotype-directed clinical applications small <br />                                              molecule inhibitors (reviewed (Haber et al., 2011).  KRAS activating mutations, <br />                                              common multiple human cancers, remain critical therapeutic challenge. <br />                                              KRAS mutations generally associated treatment-refractory tumors (Downward, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              2003). instance, KRAS mutant lung cancers generally refractory EGFR-targeted <br />                                              small molecule inhibitors colon cancer, KRAS mutations predict failure response <br />                                              antibodies targeting overexpressed wild-type EGFR (Normanno et al., 2009).  <br />                                              patients KRAS-mutant colon cancers excluded targeted EGFR therapies                                              faced limited therapeutic options. <br />  <br />  <br />  <br />  <br />                            &#194;&#169; 2012 Elsevier  rights reserved. <br />                            * <br />                             corresponding authors: Daniel Haber (Haber@helix.mgh.harvard.edu) Jeff Settleman (settleman.jeffrey@gene.com). <br />                            3Current addresses: Departmental Pharmacology Experimental Therapeutics, Division Medical Oncology Hematology, <br />                            Cancer Research Center, Boston University School Medicine, Boston MA 02118. <br />                            4Discovery Oncology, Genentech, , South San Francisco, CA 94080 <br />                            Publisher&apos;s Disclaimer: PDF file unedited manuscript accepted publication. service                            customers providing early version manuscript. manuscript undergo copyediting, typesetting, review                            resulting proof published final citable form. note production process errors                            discovered affect content, legal disclaimers apply journal pertain. <br />                             Singh et al.                                                                                          Page 2 <br />  <br />  <br />                                           <span id='am-1' about='oboInOwl:date' typeof='owl:Thing'>date</span>, pharmacologic targeting activated KRAS successful. Mutationally- <br />                                           activated KRAS proteins susceptible agents target GTPase function drug <br />                                           therapies disrupt KRAS post-translational modifications clinically <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           efficacious (Whyte et al., 1997). recently, genome-wide shRNA screens <br />                                           revealed synthetic lethal interactions knockdown candidate gene appeared                                           suppress proliferation KRAS mutant cancer cell lines (Barbie et al., 2009; Luo et al., <br />                                           2009a; Scholl et al., 2009; Singh et al., 2009). date, findings led                                           development effective inhibitors treat KRAS-mutant cancers, possibly                                           contextual complexity KRAS mutations difficulty generalizing synthetic <br />                                           lethal interactions broad range tumor-specific backgrounds. <br />  <br />                                           analyzing large panels KRAS-mutant tumor-derived cell lines, noted                                           approximately half cell lines underwent apoptosis following shRNA-mediated <br />                                           knockdown KRAS  called KRAS-dependent), half maintained <br />                                           viability (KRAS-independent) (Singh et al., 2009). differences independent                                           particular KRAS mutation, KRAS-dependent cells generally exhibited higher <br />                                           KRAS protein expression levels. Cellular context appeared play significant role                                           dependency KRAS mutant cells continued KRAS signaling survival.                                           lung pancreatic cancer cells harboring KRAS mutations, presence epithelial <br />                                           markers highly correlated KRAS dependency, epithelial mesenchymal <br />                                           transformation (EMT) associated KRAS independence, despite presence NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           KRAS mutation. Reversion mesenchymal cells epithelial phenotype associated <br />                                           restored dependence KRAS, suggesting mesenchymal-associated signals                                           provide alternative survival pathways KRAS activity disrupted (Singh et al., 2009). <br />                                           Interestingly, association KRAS dependency expression epithelial markers <br />                                           evident KRAS-mutant colon cancers prompting identifying <br />                                           lineage-specific determinants KRAS-dependency colon cancers. <br />  <br />                                           cellular context KRAS mutations colon cancer complex. APC loss function <br />                                           mutations arise early adenomas lead inappropriate activation canonical Wnt <br />                                           signaling, &#206;&#178;-catenin-mediated transcriptional changes (Behrens et al., 1996). KRAS <br />                                           mutations common progression adenoma carcinoma, occurring <br />                                           approximately 50% cases, subsequently followed frequent deletions                                           SMAD4, targeting transforming growth factor beta(TGF-&#206;&#178;) signaling pathway. <br />                                           (Vogelstein et al., 1988). contribution KRAS mutations colon carcinogenesis                                           uniquely linked altered Wnt TGF-&#206;&#178; signaling. <br />  <br />                                            compared KRAS-dependent -independent colon cancer cells using                                           combination gene expression shRNA knockdown studies, led NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           identification MAP3K7, encoding TGF-&#206;&#178; activated kinase (TAK1), driver cell <br />                                           survival KRAS-dependent, APC-deficient cells. recently reported <br />                                           enhancement Wnt signaling KRAS (Janssen et al., 2006; Phelps et al., 2009),                                           observations point unappreciated critical signaling node subset colon <br />                                           cancers. demonstrate  KRAS-dependent, KRAS-independent cells, <br />                                           KRAS activates Bone Morphogenetic Protein-7 (BMP-7) signaling, leading TAK1 <br />                                           activation, &#206;&#178;-catenin nuclear localization, transcriptional upregulation Wnt target <br />                                           genes. accompanied KRAS- TAK1-regulated activation NF-&#206;&#186;B <br />                                           pathway. Reconstitution studies confirm activation KRAS-dependent signaling <br />                                           network underlies exquisite sensitivity TAK1 inhibition.  observations <br />                                           point potential therapeutic strategy, based targeting vulnerable node                                           identifiable subset APC/KRAS mutant colon cancers. <br />  <br />  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                           Page 3 <br />  <br />  <br />                               Results <br />                               Identification KRAS-dependent colon cancer cell lines <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           used lentiviral-based shRNA assay quantitate KRAS dependency (Singh et al., <br />                                           2009) 21 KRAS-mutant colon cancer cell lines, measuring cell viability 6 days post- <br />                                           infection (Figure 1A). KRAS-mutant colon cancer cells showed variable KRAS- <br />                                           dependencies (Figures 1A 1B), allowing derive quantitative Ras Dependency <br />                                           Index (RDI) compare multiple cell lines varying viral transduction efficiencies                                            Experimental Procedures). RDI &gt;2.0 represented threshold classify cells KRAS- <br />                                           dependent. 21 KRAS-mutant cell lines, 10 classified KRAS-dependent <br />                                           11 KRAS-independent (Figure 1B). KRAS dependency associated                                           particular KRAS activating mutations (Table S2). Examples KRAS-dependent cell <br />                                           lines (SW620 SK 1) selected comparison KRAS-independent <br />                                           lines (LS-174T SW1463) (Figure 1A). <br />  <br />                                           KRAS depletion KRAS-dependent colon cancer cells triggered apoptosis, measured                                           caspase-3 polyADP ribose polymerase (PARP) cleavage 6-days following shRNA <br />                                           knockdown (Figure 1C). Cells classified KRAS-independent despite presence                                           mutant KRAS showed apoptotic response KRAS depletion. Reduced Erk Akt <br />                                           phosphorylation preceded apoptosis KRAS-dependent cells, KRAS-independent <br />                                           cells displayed weak KRAS coupling Erk phosphorylation.  KRAS <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           independent cells, KRAS depletion resulted paradoxically increased Akt phosphorylation, <br />                                           agreement recent reports (Ebi et al., 2011) (Figure 1D).  KRAS-dependent                                           -independent colon cancer cells demonstrate distinct patterns signaling downstream                                           mutant KRAS, KRAS-dependent cells showing suppression key survival <br />                                           signals following KRAS knockdown. <br />  <br />                               TAK1 KRAS dependency-associated kinase <br />                                           identify potentially &#226;&#8364;&#339;druggable&#226;&#8364;? pro-survival effectors KRAS-dependent colon cancer <br />                                           cells, compared gene expression profiles KRAS-dependent KRAS- <br />                                           independent cell lines (Figure 2A; Experimental Procedures). core &#226;&#8364;&#339;KRAS <br />                                           Dependency Gene Set&#226;&#8364;? identified, comprising 687 genes overexpressed KRAS- <br />                                           independent cells (IND genes) 832 genes overexpressed KRAS-dependent cells (DEP <br />                                           genes). Hierarchical clustering KRAS Dependency Gene Set 40 colon cancer <br />                                           cell lines wild-type mutant KRAS demonstrated 3 clusters: IND, DEP                                           intermediate (Figure S1A). Gene ontology analysis DEP gene set, using DAVID <br />                                           algorithm (Dennis et al., 2003) identified major functional classes, kinases                                           abundant (Figure S1B). selected analysis, given possibility <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           identifying novel tractable therapeutic targets. 47 DEP protein, <span id='am-2' about='obo:IMR_0001362' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-3' property="oboInOwl:hasDbXref" content="CHEBI:25054" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-5' property="obo:IAO_0000115" content="Organic molecule that is insoluble in water but tends to dissolve in nonpolar organic solvent." datatype="xsd:string"></span><span id='am-6' property="oboInOwl:id" content="IMR:0001362" datatype="xsd:string"></span><span id='am-7' property="rdfs:label" content="lipid" datatype="xsd:string"></span>lipid</span> <span id='am-26' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-27' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-28' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-29' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-30' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-32' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span>nucleotide</span> <br />                                           kinase genes showed significant overexpression KRAS-dependent colon cancer cells, <br />                                           confirmed subset protein level (Figures 2B C). DEP gene set <br />                                           prominently featured genes relevant mitotic checkpoint control DNA replication/ <br />                                           repair pathways (KEGG pathway database) (Figure S1C). note, Wnt signaling <br />                                           components significantly enriched KRAS-dependent cells, compared KRAS- <br />                                           independent cells, despite classes having comparable frequency APC mutations <br />                                           (Figure S1C). <br />  <br />                                           selected candidate protein kinase-encoding genes list 47, based                                           ranking DEP scores literature searches genes putative cancer- <br />                                           associated function. establish functional relevance DEP kinases,                                           compared consequences knockdown cell lines comparable lentiviral <br />                                           infection profiles (KRAS-independent SW837 cells KRAS-dependent SW620 cells; <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                            Page 4 <br />  <br />  <br />                                           Figures S1D-F). targeted 17 kinases, using 5 shRNAs 3 different viral MOIs, <br />                                           measuring relative cell densities 6 days post-infection (Figure S1E S1F).                                           kinases tested, TAK1 (MAP3K7) depletion potent selective effect NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           viability SW620 versus SW837 cells, measured cumulative effect shRNA <br />                                           constructs tested (Figure 2D). genes, VRK2 encoding vaccinia related kinase <br />                                           isoform 2 CHUK encoding &#206;&#186;B kinase alpha, demonstrated selective albeit                                           potent effects SW620 cell viability (Figures S1E, S1F 2D). TAK1 depletion                                           KRAS-dependent SW620 cells remarkable producing strong, viral titer-dependent <br />                                           apoptotic response, assessed PARP cleavage (Figure 2E).                                           functionally validated kinase-encoding genes original list 47, remains <br />                                           formally possible additional untested kinases play stronger pro-survival roles                                           tested. <br />  <br />                               Validation TAK1 therapeutic target KRAS-dependent colon cancer <br />                                           validate TAK1 candidate therapeutic target context, used potent <br />                                           selective TAK1 kinase inhibitor, 5Z-7-oxozeaenol (Rawlins et al., 1999). tested <br />                                           sensitivity 5Z-7-oxozeaenol panel 47 colon cancer cell lines various <br />                                           genotypes (Figures 3A S2A). KRAS BRAF genotypes procured                                           Sanger Institute&apos;s Catalog Somatic Mutations (COSMIC) determined targeted <br />                                           resequencing (Table S2). KRAS-mutant cells, classified KRAS-dependent <br />                                           virtue sensitivity KRAS shRNA knockdown highly sensitive TAK1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           inhibition, KRAS-independent cells generally resistant (P&lt;0.0001). Notably, <br />                                           10 BRAF-mutant cell lines tested, 5 sensitive 5Z-7-oxozeaenol (Figure 3A). <br />                                           majority cells wild-type KRAS BRAF 5Z-7-oxozeaenol-resistant, <br />                                           mutations potentially impact Ras pathway (e.g. NF1 mutation                                           HT55 cells ALK mutation CoCM-1 cells &#226;&#8364;&#8220; COSMIC, Sanger Institute)                                           moderately sensitive 5Z-7-oxozeaenol. Consistent colon cancer derivation, <br />                                           cell lines tested harbored APC mutations; note, cell lines wild-type <br />                                           APC harboring downstream CTNNB1 (&#206;&#178;-catenin) activating mutations  S33Y                                           S45 missense mutations) resistant TAK1 inhibition (Table S2). <br />  <br />                                           determine sensitivity TAK1 inhibition specific colon cancer-derived cell lines, <br />                                           assessed sensitivity 5Z-7-oxozeaenol 5 KRAS mutant pancreatic ductal <br />                                           adenocarcinoma (PDAC) 4 non-small cell lung cancer (NSCLC) cells,                                           APC wild-type (Figure S2B). previously classified KRAS-dependent - <br />                                           independent (Singh et al., 2009), PDAC NSCLC cells largely refractory 5Z-7- <br />                                           oxozeaenol treatment. Finally, non-transformed epithelial cell lines 5Z-7- <br />                                           oxozeaenol-refractory &#226;&#8364;&#8220; MCF10A (IC50 = 5.5&#206;&#188;M) MDCK (IC50 = 22&#206;&#188;M) (Figure <br />                                           S2A). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Pharmacologic TAK1 inhibition triggered apoptosis KRAS-dependent colon cancer cells, <br />                                           measured PARP caspase-3 cleavage (Figure 3B). cells, 5Z-7-oxozeaenol <br />                                           treatment caused reduced threonine 172 phosphorylation <span id='am-8' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-9' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-11' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-14' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span>AMP</span>-activated kinase (p- <br />                                           AMPK), established TAK1 regulated kinase (Xie et al., 2006). contrast, KRAS- <br />                                           independent cells displayed little 5Z-7-oxozeaenol-mediated caspase-3 PARP <br />                                           cleavage, high doses, AMPK phosphorylation unaffected.  low <br />                                           concentrations 5Z-7-oxozeaenol, range 0.625 1.25 &#206;&#188;M, promote apoptosis <br />                                           selectively KRAS-dependent colon cancer cells. <br />  <br />                                           validate efficacy 5Z-7-oxozeaenol vivo, generated subcutaneous xenografted <br />                                           tumors NOD/SCID mice using representative KRAS mutant cell lines: HCT8                                           SW837 (KRAS-independent), SK 1 SW620 (KRAS-dependent) (Figure 3C). <br />                                           Palpable tumors evident weeks post-implantation, time mice treated <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                          Page 5 <br />  <br />  <br />                                           daily intraperitoneal 15mg/kg 5Z-7-oxozeaenol vehicle (Rawlins et <br />                                           al., 1999). Tumor imaging demonstrated remarkable regression KRAS-dependent <br />                                           tumors 6 days treatment. contrast, tumors derived KRAS- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           independent cell lines showed significant response TAK1 inhibition. overt toxicity <br />                                           evident 5Z-7-oxozeaenol-treated mice selected dosing regimen. <br />  <br />                               gene expression signature associated sensitivity TAK1 inhibition <br />                                           identify molecular mechanisms underlying sensitivity TAK1 inhibition, isolated <br />                                           subsets genes KRAS DEP gene set highly correlated 5Z-7- <br />                                           oxozeaenol sensitivity. employed K-means clustering (Gasch Eisen, 2002)                                           unsupervised pattern recognition KRAS dependency gene set test set 21 colon <br />                                           cancer cell lines sensitivity TAK1 inhibition determined (Figure S3A). <br />                                           setting parameters k=3 clusters, identified 10 nodes (0 9) representing <br />                                           synexpression groups regulated genes. correlated average expression scores <br />                                           genes node IC50 values 5Z-7-oxozeaenol linear regression <br />                                           modeling, computed coefficients determination (r2) p-values node/ <br />                                           IC50 correlation (Figure S3B). analysis revealed nodes genes (Figure S3B                                           C) expression strongly correlated sensitivity TAK1 inhibition.                                           combined genes nodes generate 32 gene &#226;&#8364;&#339;TAK1 dependency signature&#226;&#8364;?. <br />  <br />                                           Clustering 32 genes 21 colon cancer cell lines demonstrated high degree NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           concordance expression TAK1 dependency gene set, sensitivity TAK1 <br />                                           inhibition degree KRAS dependency (Figure 4A). Average expression                                           TAK1 dependency signature significantly correlated previously derived RDI <br />                                           values KRAS mutant cell lines shown Figure 4A (P&lt;0.0001, Figure S3E).                                           general classes cell lines appear analysis: KRAS-dependent, TAK1 inhibitor- <br />                                           sensitive cell lines highest expression TAK1 dependency signature; KRAS- <br />                                           independent, TAK1 inhibitor-refractory cells weak expression signature;                                           cluster cell lines intermediate levels expression, demonstrating enrichment                                           BRAF mutations (4 6 cell lines). <br />  <br />                                           Wnt pathway enrichment KRAS-dependent cells (Figure S1C),                                           overlapped TAK1 dependency signature dataset binding sites Wnt- <br />                                           regulated transcription factor TCF4, derived ChIP Chip analyses (Hatzis et al., <br />                                           2008). 32 TAK1 dependency genes, 18 contained proximal TCF4 binding sites.                                           number genes, BAMBI, PROX1 NAV2 (HELAD1)                                           previously linked colon tumorigenesis context deregulated Wnt signaling (Lin et <br />                                           al., 2008; Petrova et al., 2008; Sekiya et al., 2004).  KRAS-dependent <br />                                           cell lines higher basal Wnt signaling activity KRAS-independent cell lines NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           measured FLASH TCF4-responsive luciferase assays (Figure 4B). <br />  <br />                                           Remarkably, applied primary colon cancer dataset (Reid et al., 2009), TAK1 <br />                                           dependency signature distinguished tumors mutations APC KRAS                                           APC mutations (Figure S3C). particular, subset TAK1 dependency <br />                                           genes identified Wnt targets expressed higher levels APC/KRAS mutant <br />                                           primary colon cancers compared APC mutant/KRAS wild-type tumors (Figure 4C). <br />                                           observations imply increased Wnt signaling KRAS-mutant cancers, note <br />                                           established Wnt target genes (e.g. MYC TCF7 (Figure S3D))                                           enriched APC/KRAS mutant tumors. Taken altogether, gene expression analyses <br />                                           suggest combination APC KRAS mutations colon cancers associated <br />                                           Wnt pathway hyperactivation correlated susceptibility TAK1 inhibition. <br />  <br />  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                           Page 6 <br />  <br />  <br />                               KRAS TAK1 regulate &#206;&#178;-catenin transcriptional activity nuclear localization <br />                                           explore role KRAS TAK1 modulating Wnt signaling, assessed                                           effect KRAS depletion &#206;&#178;-catenin/TCF transcription panel KRAS mutant cell <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           lines using FLASH reporter (Figures 5A S4A). KRAS-dependent cells <br />                                           SW1116 SK 1 exhibited decreased FLASH reporter activity following KRAS <br />                                           depletion, correlated level KRAS knockdown (Figure 5A).                                           contrast, KRAS depletion effect KRAS-independent line (SW1463)                                           increased FLASH activity (LS174T). KRAS-dependent cells, 24h 5Z-7- <br />                                           oxozeaenol treatment strongly suppressed FLASH activity dose-dependent manner <br />                                           (IC50 0.8&#206;&#188;M 2.5&#206;&#188;M) (Figure 5B). contrast, TAK1 inhibition weaker effect <br />                                           FLASH activity KRAS-independent cells (IC50 &gt; 10&#206;&#188;M). note, SW837 cells <br />                                           exhibited biphasic response 5Z-7-oxozeaenol, increased FLASH activity                                           low doses reduced activity high dose 5&#206;&#188;M. define effect TAK1 <br />                                           signaling physiological Wnt target gene, measured protein expression levels                                           endogenous Axin 2 gene (Lustig et al., 2002), following treatment 5Z-7-oxozeaenol. <br />                                           TAK1 inhibition resulted dose-dependent reduction Axin 2 expression KRAS- <br />                                           dependent cells, KRAS-independent cells (Figure 5C).  KRAS                                           TAK1 suppression selectively suppress &#206;&#178;-catenin-mediated transcription Wnt target <br />                                           gene expression KRAS-dependent cells. <br />  <br />                                           activation Wnt signaling associated nuclear translocation &#206;&#178;-catenin, NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           analyzed subcellular localization following TAK1 suppression immunofluorescence <br />                                           microscopy. Parental vehicle-treated KRAS-dependent SW1116 SK 1 cells <br />                                           nuclear &#206;&#178;-catenin localization, addition localization E-cadherin                                           adherens junctions. TAK1 inhibition cells resulted loss nuclear &#206;&#178;-catenin <br />                                           24h. effect seen KRAS-independent LS174T SW1463 cells. <br />                                           (Figures 5D S4B).  inhibition TAK1 signaling causes reduced &#206;&#178;-catenin nuclear <br />                                           localization KRAS-dependent KRAS-independent cells. <br />  <br />                               Reconstitution TAK1 dependency KRAS Wnt activation <br />                                           determine TAK1-independent cells driven TAK1 dependency <br />                                           enhanced KRAS/Wnt signaling, undertook series reconstitution experiments. <br />                                           HT29 C2BBe1 colon cancer cells, mutant APC wild-type KRAS, exhibit                                           little basal TCF/LEF reporter activity demonstrate low undetectable nuclear &#206;&#178;-catenin <br />                                           signal (Figures 5H S4D). cell lines insensitive 5Z-7-oxozeaenol.                                           determine activation KRAS sufficient increase Wnt signaling                                           lead sensitivity TAK1 inhibition, ectopically introduced mutant KRAS(G12V)                                           HT29 cells phosphoglycerate kinase (PGK) promoter-driven expression. Expression <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           4A 4B splice isoforms mutant KRAS cells resulted 3-fold <br />                                           reduction IC50 5Z-7-oxozeaenol (Figures S4C 5E). contrast, ectopic <br />                                           expression mutant NRAS equivalent expression levels caused slightly increased <br />                                           resistance 5Z-7-oxozeaenol. <br />  <br />                                           increased TAK1 dependency resulting ectopic mutant KRAS HT29 cells                                           correlated 5-fold upregulated &#206;&#178;-catenin transcriptional activity, blocked                                           dose-dependent manner TAK1 inhibition (Figures 5F). Similar results obtained                                           second KRAS wild-type, TAK1-independent cell line (C2BBe1) (Figures S4D). Ectopic <br />                                           expression mutant KRAS resulted increased TAK1 autophosphorylation, Erk <br />                                           phosphorylation, elevated Axin 2 levels nuclear &#206;&#178;-catenin localization (Figures 5G                                           5H). TAK1 inhibition reversed KRAS-induced &#206;&#178;-catenin nuclear localization. Finally, <br />                                           pretreatment cells 5Z-7-oxozeaenol, prior transduction mutant KRAS, <br />                                           abrogated KRAS-mediated increase Wnt signaling (Figure S4E). Taken  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                         Page 7 <br />  <br />  <br />                                           ectopic expression mutant KRAS sufficient activate TAK1 APC-deficient cells, <br />                                           leading increased Wnt signaling sensitization TAK1 inhibition. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           test role Wnt signaling context, investigated KRAS mutant <br />                                           pancreatic cancer (PDAC) cell lines, PANC-1 YAPC, APC wild-type. <br />                                           PANC-1 cells KRAS-independent, YAPC cells KRAS-dependent,                                           distinction linked increased KRAS signaling YAPC cells (Singh et al., <br />                                           2009). Activation canonical Wnt signaling inhibition GSK-3 using selective <br />                                           inhibitor BIO caused strong, dose-dependent FLASH reporter induction KRAS- <br />                                           dependent YAPC cells, compared weak induction KRAS-independent PANC-1 <br />                                           cells (Figure S4F). Simultaneous treatment YAPC cells 5Z-7-oxozeaenol abrogates <br />                                           BIO-mediated FLASH induction. contrast, PANC-1 cells undergo stronger <br />                                           induction FLASH activity combined GSK-3 TAK1 inhibition (Figure S4G, <br />                                           lower upper panel). viability KRAS-dependent YAPC cells greatly <br />                                           suppressed combined GSK-3 TAK1 inhibition, effect seen                                           PANC-1 cells (Figure S5H). Finally, introduced constitutively-activated mutant &#206;&#178;- <br />                                           catenin (CTNNB1-CA) containing S33Y S45A missense mutations, KRAS- <br />                                           dependent SW620 cells. mutant caused partial losses KRAS TAK1 <br />                                           dependencies (Figures S6A-C). Taken altogether, reconstitution studies indicate                                           KRAS Wnt pathway hyperactivation contribute TAK1 dependency. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               KRAS activates TAK1 enhanced BMP signaling <br />                                           TAK1 encodes effector BMP receptor, activated response BMP <br />                                           ligand binding. TAK1 dependency signature notably enriched TGF-&#206;&#178;/BMP <br />                                           pathway components, including BMP7, BAMBI INHBB (Figure 4A). test                                           direct role BMP pathway KRAS-mediated activation TAK1, measured                                           expression BMP receptor ligand BMP7 markers BMP activation following <br />                                           KRAS depletion. KRAS-dependent SW620 SK 1 cells, KRAS depletion caused <br />                                           reduced BMP-7 expression, BMP-mediated phosphorylation effector Smad1,                                           TAK1 autophosphorylation (Figure 6A). note, predominant phospho-TAK1 <br />                                           immunoreactive band context 40kD isoform, isoforms (40kD                                           75kD) observed depleted TAK1 shRNA (Figure 2E). Finally, Axin 2 levels                                           suppressed following KRAS depletion, indicating KRAS signaling enhances BMP <br />                                           signaling Wnt activation (Figure 6A). effects KRAS depletion seen                                           KRAS-independent LS-174T SW837 cells. <br />  <br />                                           Given observed KRAS-regulated expression BMP7 SW620 cells, tested                                           functional role ligand using lentiviral shRNA-mediated knockdown (Figure 6B). <br />                                           BMP-7 depletion using panel 5 different shRNAs caused pronounced viral titer- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           dependent apoptosis (Figure 6B). Similarly, knockdown BMPR1A, encoding BMP <br />                                           receptor type 1A (Alk-3) component KRAS dependency gene set, <br />                                           suppressed proliferation viability KRAS-dependent SW620 cells (Figure 2D).                                           KRAS-independent SW837 cells did observe significant proliferation viability <br />                                           defects following BMP7 depletion (Figure S5A S5B).  autocrine BMP-7 ligand <br />                                           expression receptor activation required maintain viability KRAS-dependent <br />                                           cells. <br />  <br />                                           determine BMP-7 induction direct consequence KRAS activation,                                           opposed indirect effect cell transformation, introduced inducible mutant <br />                                           KRAS-estrogen receptor chimera (ER-KRAS(12V)) HT29 cells, normally <br />                                           express wild-type endogenous KRAS. 24h following KRAS induction using 4- <br />                                           hydroxytamoxifen (4-HT), BMP7 mRNA levels increased, cellular                                           secreted BMP-7 protein levels (Figure 6C). Endogenous levels Axin 2  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                          Page 8 <br />  <br />  <br />                                           increased following KRAS induction, FLASH reporter activity. activation <br />                                           downstream markers Wnt signaling inducible KRAS effectively <br />                                           suppressed depletion BMP7, BMPR1A TAK1 (Figure 6D), consistent NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           function key mediators KRAS-potentiated Wnt pathway activation. <br />  <br />                                           define role BMP signaling TAK1 dependency, ectopically expressed <br />                                           constitutively-activated (CA) variant (Q233D) BMPR1A (Zou et al., 1997) HT29 <br />                                           cells. Expression BMPR1A-CA conferred increased sensitivity 5Z-7-oxozeaenol                                           IC50 value 1.1&#206;&#188;M compared 7.7&#206;&#188;M vector control cells (Figure 6E). TAK1 <br />                                           inhibition BMPR1A-CA-expressing cells resulted apoptosis shown caspase-3                                           PARP cleavage (Figure 6F). accompanied dose-dependent decreases Axin 2 <br />                                           phosphorylated Smad2 levels. Finally, BMPR1A-CA-induced nuclear accumulation                                           &#206;&#178;-catenin, suppressed following TAK1 inhibition (Figure 6G).  APC- <br />                                           mutant cells low baseline &#206;&#178;-catenin transcriptional activity, artificial BMP activation <br />                                           enhances Wnt signaling TAK1 activation, conferring TAK1 dependency. <br />                                           Surprisingly, introduction BMPR1A-CA KRAS-dependent SW620 cells                                           rescue KRAS depletion-induced cell death (Figure 6D), suggesting BMP receptor <br />                                           activation necessary sufficient promote cell survival KRAS-dependent <br />                                           cancer cells. summary, mutant KRAS promotes autocrine BMP signaling causing TAK1 <br />                                           activation leading enhanced Wnt signaling APC-deficient colon cancer cells.                                           KRAS-dependent cells, components necessary anti-apoptotic <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           signaling. <br />  <br />                               Discussion <br />                                           analyzing KRAS-dependent subset KRAS-mutant colon cancer cells,                                           uncovered pathway KRAS enhances Wnt activity BMP/TAK1 <br />                                           activation. Approximately half colon cancer cell lines KRAS APC <br />                                           mutations appear rely pathway viability, rendering sensitive TAK1 <br />                                           kinase inhibition.  TAK1 inhibition provide clinical paradigm context- <br />                                           dependent targeting KRAS-dependent colon cancers. data suggest TAK1 <br />                                           functions pro-survival mediator cancer cells displaying hyperactive KRAS-dependent <br />                                           Wnt signaling. seen basal conditions colon cancers relevant <br />                                           genotypes synthetically achieved activating Wnt signaling GSK3 kinase <br />                                           inhibition KRAS-dependent/APC-wild-type pancreatic cancer cells enforced <br />                                           expression mutant KRAS APC mutant/KRAS wild-type colon cancer cells. ability <br />                                           reconstitute pathway dependency unusual &#226;&#8364;&#339;oncogene addiction&#226;&#8364;? models,                                           facilitates molecular dissection critical signaling components drive drug <br />                                           susceptibility. underlying basis explained emerging concept NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           &#226;&#8364;&#339;non-oncogene addiction&#226;&#8364;?, describing acquired dependence cells non-mutated <br />                                           genes drive malignant progression, function essential                                           cell tolerate oncogenic stress-induced states (Luo et al., 2009b). TAK1 <br />                                           dependency restricted colon cancer, elevated Wnt signaling activity                                           KRAS-dependent colon cancer cells highlights importance cellular context                                           role lineage-specific pathways informing effective therapeutic strategy. <br />  <br />                                           combination knockdown reconstitution experiments, attempted                                           dissect key signaling components linking mutant KRAS TAK1 Wnt activation <br />                                           (Figures S6 7). strong relationship Wnt KRAS signaling underscored <br />                                           observation constitutive activation Wnt signaling causes loss KRAS <br />                                           dependency KRAS-dependent colon cancer cells. data indicate KRAS regulates <br />                                           TAK1 Wnt signaling APC-deficient cells upregulation BMP-7 levels BMP <br />                                           receptor activation.  BMP receptor activation necessary KRAS- <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                            Page 9 <br />  <br />  <br />                                           driven survival signaling, sufficient.  network KRAS-regulated signaling <br />                                           components likely contribute tumor cell survival. instance, KRAS regulates NF- <br />                                           &#206;&#186;B TAK1 activation (Figures S6E 7). relative contribution NF-&#206;&#186;B <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           pathway KRAS-driven survival signaling remains determined, evidence <br />                                           suggests pathway critical KRAS-driven lung tumorigenesis (Meylan et al., <br />                                           2009; Starczynowski et al., 2011). Additional parallel pathways likely components <br />                                           KRAS-TAK1 survival signaling axis, data suggest Wnt pathway <br />                                           activation critical. <br />  <br />                                           studies highlight context-specific role KRAS driving Wnt signaling                                           sensitized background APC deficiency. consistent recent studies reporting <br />                                           KRAS-mediated enhancement Wnt signaling zebrafish developmental model (Phelps <br />                                           et al., 2009).  observed APC-deficient colon cancers low &#206;&#178;-catenin <br />                                           activity, introduction mutant KRAS causes sharp increase levels nuclear &#206;&#178;-catenin, <br />                                           accompanied increased TCF/LEF transcriptional activity. effect partly involves <br />                                           KRAS-mediated regulation BMP signaling subsequent TAK1 activation, leading <br />                                           enhanced TCF/LEF activity. Interestingly, C. elegans TAK1 ortholog Mom-4 <br />                                           promotes nuclear retention &#206;&#178;-catenin ortholog Wrm-1 asymmetrically 2-cell <br />                                           stage EMS cell defining polarity axis specification (Nakamura et al., <br />                                           2005; Shin et al., 1999). context-specific TAK1/&#206;&#178;-catenin interaction points                                           remarkable degree evolutionary conservation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           clinical perspective, role secreted BMP-7 particular                                           autocrine paracrine activation pathway detectable targetable                                           tumors. Importantly, expression BMP pathway components help stratify colon <br />                                           cancer patients TAK1 inhibitor response groups. end, suggest 10 <br />                                           genes vitro derived TAK1 dependency signature (GGH, BMP7, BAMBI, <br />                                           MBOAT2, HSPA12A, FYN, NAV2, RGL1, SYK RUNX1) provide clinically <br />                                           annotated signature TAK1 inhibitors sufficiently developed clinical trials.                                           eventually applied clinical diagnostic test measure relative mRNA levels <br />                                           corresponding gene TAK1 dependency signature patient tumors. note                                           half KRAS mutant colon cancer cell lines KRAS-dependent                                           sensitive TAK1 inhibition, account quarter colon <br />                                           cancers.  guided accurate molecular profiles, TAK1 inhibitors provide <br />                                           significant clinical benefit recalcitrant form colon cancer. tool <br />                                           compounds 5Z-7-oxozeaenol, synthetic TAK1 inhibitors tested                                           preclinical models (Melisi et al., 2011).  given potential toxicity, administration <br />                                           regimens need modeled using highly TAK1-dependent cancers. Finally, study <br />                                           illustrates presence KRAS mutation does identify homogenously drug- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           resistant tumor type, specific histological type. Instead, degrees KRAS <br />                                           dependency different cancers modulated associated signaling pathways                                           Wnt pathway colon cancers. adds complexity analysis ultimately <br />                                           expected inform unique therapeutic opportunities. <br />  <br />                               Experimental Procedures <br />                               Derivation Ras Dependency Index (RDI) <br />                                           Weighted averages relative cell densities MOIs 5 1 KRAS B <br />                                           shRNAs calculated. inverse averages calculated. number <br />                                           multiplied transduction efficiency respective cell line  proportion                                           cells expressing control shRNA following puromycin selection compared                                           treated puromycin), yielding RDI value. RDI 2 calibrated 50% <br />                                           reduction cellular proliferation following KRAS depletion. <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                                         Page 10 <br />  <br />  <br />                               Gene Expression Microarray Analyses <br />                                           Comparative genome expression profiling performed Affymetrix U133A <br />                                           Microarrays. dataset colon cancer cell lines used publically available <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           BROAD Institute (http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi)                                           Sanger Cell Line Project. Expression data normalized using GCRMA (Bolstad et al., <br />                                           2003). derive KRAS dependency gene set, p-values computed comparing <br />                                           average normalized probe intensity probe set cell lines shown Figure <br />                                           2A. Fold differences average probe intensities calculated. p-value &#226;&#710;&#8217;log <br />                                           transformed fold difference log2 transformed. product log-transformed <br />                                           values designated &#226;&#8364;&#339;DEP SCORE&#226;&#8364;? (Table S1) genes ranked based                                           score. Significantly  expressed genes (p&lt;0.05; fold difference&gt;2)                                           identified method. generate heatmaps, complete linkage hierarchical clustering                                           Euclidean city-block distance performed using Cluster (Eisen et al., 1998) Java <br />                                           Treeview (http://sourceforge.net/projects/jtreeview/). Statistical analyses correlations                                           gene expression data performed Graphpad Prism. Patient data available <br />                                           NCBI GEO database (accession #: GSE16125). <br />  <br />                               vivo Pharmacology Xenografted Mouse Tumors <br />                                           Human colorectal cancer tumor cells trypsinized resuspended single cell <br />                                           suspensions injected left right flanks NOD/SCID mice. Mice housed NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           pathogen-free environment Massachusetts General Hospital handled                                           strict accordance Good Animal Practice defined Office Laboratory Animal <br />                                           Welfare, animal experiments approval Massachusetts General <br />                                           Hospital Subcommittee Research Animal Care. Tumor size monitored daily                                           tumor volume reached approximately 200mm3, treatment 5Z-7-oxozeaenol <br />                                           initiated (7 14 days post-implantation). Mice injected daily 15mg/kg 5Z-7- <br />                                           oxozeaenol intraperitoneal administration. <br />  <br />                               Reporter assays <br />                                           FLASH NF-&#206;&#186;B reporter assays, cells transfected 0.5&#206;&#188;g <br />                                           FOP-FLASH FLASH plasmids pGL3-&#206;&#186;B-LUC plus 50ng pRL-TK <br />                                           (expressing Renilla luciferase). Normalized luciferase activity obtained using                                           Dual-Luciferase Reporter Assay (Promega . Alternatively, stable cell lines <br />                                           expressing FLASH reporter generated transducing cells 7TFP (Fuerer <br />                                           Nusse, 2010) recombinant lentiviruses followed drug selection. <br />  <br />                               Supplementary Material <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                           work supported NIH K99 CA149169 S. NIH R01 CA109447 Lustgarten <br />                                           Foundation grant J.S NIH R01 CA129933 D H. grateful Randall Peterson, David Ting                                           Andre Bernards critical evaluation comments manuscript. thank Laura Libby Brian <br />                                           Brannigan technical assistance mouse xenograft experiments KRAS/BRAF sequencing analyses, <br />                                           respectively. thank Vijay Yajnik providing FLASH reporter plasmids. Finally, thank Kevin <br />                                           Haigis, Moon Yee Hang, Miguel Rivera, Jianmin Zhang, Mingzhu Liu Matt Zubrowski intellectual                                           technical advice. <br />  <br />  <br />  <br />  <br />                                                    Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                                 Page 11 <br />  <br />  <br />                               References <br />                                           Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn  Schinzel AC, Sandy P, Meylan E, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Scholl C, et al. Systematic RNA interference reveals oncogenic KRAS-driven cancers require <br />                                              TBK1. Nature. 2009; 462:108&#226;&#8364;&#8220;112. [PubMed: 19847166] <br />                                           Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional <br />                                              interaction beta-catenin transcription factor LEF-1. Nature. 1996; 382:638&#226;&#8364;&#8220;642. <br />                                              [PubMed: 8757136] <br />                                           Bolstad BM, Irizarry RA, Astrand M, Speed TP. comparison normalization methods high <br />                                              density oligonucleotide array data based variance bias. Bioinformatics. 2003; 19:185&#226;&#8364;&#8220;193. <br />                                              [PubMed: 12538238] <br />                                           Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, <br />                                              Kaufman PD. versatile viral expression depletion proteins mammalian cells. <br />                                              PLoS  2009; 4:e6529. [PubMed: 19657394] <br />                                           Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database <br />                                              Annotation, Visualization, Integrated Discovery. Genome Biol. 2003; 4:P3. [PubMed: <br />                                              12734009] <br />                                           Downward J. Targeting RAS signalling pathways cancer therapy. Nat Rev Cancer. 2003; 3:11&#226;&#8364;&#8220;22. <br />                                              [PubMed: 12509763] <br />                                           Ebi H, Corcoran RB, Singh  Chen  Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, <br />                                              Settleman J, et al. Receptor tyrosine kinases exert dominant control PI3K signaling human <br />                                              KRAS mutant colorectal cancers. J Clin Invest. 2011; 121:4311&#226;&#8364;&#8220;4321. [PubMed: 21985784] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis display genome-wide <br />                                              expression patterns. Proc Natl Acad Sci U S  1998; 95:14863&#226;&#8364;&#8220;14868. [PubMed: 9843981] <br />                                           Fuerer C, Nusse R. Lentiviral vectors probe manipulate Wnt signaling pathway. PLoS  <br />                                              2010; 5:e9370. [PubMed: 20186325] <br />                                           Gasch AP, Eisen MB. Exploring conditional coregulation yeast gene expression fuzzy <br />                                                k-means clustering. Genome Biol. 2002; 3 RESEARCH0059. <br />                                           Haber DA, Gray NS, Baselga J. evolving war cancer. Cell. 2011; 145:19&#226;&#8364;&#8220;24. [PubMed: <br />                                                21458664] <br />                                           Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, <br />                                                Santo EE, Welboren W, et al. Genome-wide pattern TCF7L2/TCF4 chromatin occupancy                                                colorectal cancer cells. Mol Cell Biol. 2008; 28:2732&#226;&#8364;&#8220;2744. [PubMed: 18268006] <br />                                           Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, <br />                                                Smits R, et al. APC oncogenic KRAS synergistic enhancing Wnt signaling intestinal <br />                                                tumor formation progression. Gastroenterology. 2006; 131:1096&#226;&#8364;&#8220;1109. [PubMed: 17030180] <br />                                           Lin  Gao C, Ning Y, X, Wu W, Chen YG. pseudoreceptor BMP activin membrane- <br />                                                bound inhibitor positively modulates Wnt/beta-catenin signaling. J Biol Chem. 2008; 283:33053&#226;&#8364;&#8220; <br />                                                33058. [PubMed: 18838381] <br />                                           Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ. NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                genome-wide RNAi screen identifies multiple synthetic lethal interactions Ras oncogene. <br />                                                Cell. 2009a; 137:835&#226;&#8364;&#8220;848. [PubMed: 19490893] <br />                                           Luo J, Solimini NL, Elledge SJ. Principles cancer therapy: oncogene non-oncogene addiction. <br />                                                Cell. 2009b; 136:823&#226;&#8364;&#8220;837. [PubMed: 19269363] <br />                                           Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van Wetering M, Clevers H, Schlag <br />                                                PM, Birchmeier W, et al. Negative feedback loop Wnt signaling upregulation                                                conductin/axin2 colorectal liver tumors. Mol Cell Biol. 2002; 22:1184&#226;&#8364;&#8220;1193. [PubMed: <br />                                                11809809] <br />                                           Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, Budillon  Abbruzzese JL, Chiao PJ. <br />                                                Modulation pancreatic cancer chemoresistance inhibition TAK1. J Natl Cancer Inst. 2011; <br />                                                103:1190&#226;&#8364;&#8220;1204. [PubMed: 21743023] <br />                                           Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. Requirement NF-kappaB <br />                                                signalling mouse model lung adenocarcinoma. Nature. 2009; 462:104&#226;&#8364;&#8220;107. [PubMed: <br />                                                19847165] <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                                   Page 12 <br />  <br />  <br />                                           Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer  Hinkle G, Piqani B, Eisenhaure TM, Luo <br />                                               B, Grenier JK, et al. lentiviral RNAi library human mouse genes applied arrayed <br />                                               viral high-content screen. Cell. 2006; 124:1283&#226;&#8364;&#8220;1298. [PubMed: 16564017] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Nakamura K, Kim S, Ishidate T, Bei Y, Pang K, Shirayama M, Trzepacz C, Brownell DR, Mello CC. <br />                                               Wnt signaling drives WRM-1/beta-catenin asymmetries early C. elegans embryos. Genes Dev. <br />                                               2005; 19:1749&#226;&#8364;&#8220;1754. [PubMed: 16077004] <br />                                           Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. vivo gene <br />                                               delivery stable transduction nondividing cells lentiviral vector. Science. 1996; <br />                                               272:263&#226;&#8364;&#8220;267. [PubMed: 8602510] <br />                                           Normanno N, Tejpar S, Morgillo F, Luca  Van Cutsem E, Ciardiello F. Implications KRAS <br />                                               status EGFR-targeted therapies metastatic CRC. Nat Rev Clin Oncol. 2009; 6:519&#226;&#8364;&#8220;527. <br />                                               [PubMed: 19636327] <br />                                           Petrova TV, Nykanen  Norrmen C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe <br />                                               F, von Melchner H, Gradwohl G, et al. Transcription factor PROX1 induces colon cancer <br />                                               progression promoting transition benign highly dysplastic phenotype. Cancer Cell. <br />                                               2008; 13:407&#226;&#8364;&#8220;419. [PubMed: 18455124] <br />                                           Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval  Rai K, Broadbent T, Sarkar S, Burt <br />                                               RW, Jones DA. step model colon adenoma initiation progression caused APC <br />                                               loss. Cell. 2009; 137:623&#226;&#8364;&#8220;634. [PubMed: 19450512] <br />                                           Rawlins P, Mander T, Sadeghi R, Hill S, Gammon G, Foxwell B, Wrigley S, Moore M. Inhibition                                               endotoxin-induced TNF-alpha production macrophages 5Z-7-oxo-zeaenol fungal <br />                                               resorcylic acid lactones. Int J Immunopharmacol. 1999; 21:799&#226;&#8364;&#8220;814. [PubMed: 10606001] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Reid JF, Gariboldi M, Sokolova V, Capobianco P, Lampis  Perrone F, Signoroni S, Costa  Leo E, <br />                                               Pilotti S, et al. Integrative approach prioritizing cancer genes sporadic colon cancer. Genes <br />                                               Chromosomes Cancer. 2009; 48:953&#226;&#8364;&#8220;962. [PubMed: 19672874] <br />                                           Scholl C, Frohling S, Dunn  Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, <br />                                               Ramaswamy S, et al. Synthetic lethal interaction oncogenic KRAS dependency                                               STK33 suppression human cancer cells. Cell. 2009; 137:821&#226;&#8364;&#8220;834. [PubMed: 19490892] <br />                                           Sekiya T, Adachi S, Kohu K, Yamada T, Higuchi O, Furukawa Y, Nakamura Y, Nakamura T, Tashiro <br />                                               K, Kuhara S, et al. Identification BMP activin membrane-bound inhibitor (BAMBI),                                               inhibitor transforming growth factor-beta signaling, target beta-catenin pathway                                               colorectal tumor cells. J Biol Chem. 2004; 279:6840&#226;&#8364;&#8220;6846. [PubMed: 14660579] <br />                                           Shin TH, Yasuda J, Rocheleau CE, Lin R, Soto M, Bei Y, Davis RJ, Mello CC. MOM-4, MAP <br />                                               kinase kinase kinase-related protein, activates WRM-1/LIT-1 kinase transduce anterior/posterior <br />                                               polarity signals C. elegans. Mol Cell. 1999; 4:275&#226;&#8364;&#8220;280. [PubMed: 10488343] <br />                                           Singh  Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. gene expression <br />                                               signature associated &#226;&#8364;&#339;K-Ras addiction&#226;&#8364;? reveals regulators EMT tumor cell survival. <br />                                               Cancer Cell. 2009; 15:489&#226;&#8364;&#8220;500. [PubMed: 19477428] <br />                                           Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, <br />                                               Gazdar AF, Lam WL, et al. TRAF6 amplified oncogene bridging RAS NF-kappaB <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               pathways human lung cancer. J Clin Invest. 2011; 121:4095&#226;&#8364;&#8220;4105. [PubMed: 21911935] <br />                                           Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, <br />                                               Smits  Bos JL. Genetic alterations colorectal-tumor development. N Engl J Med. 1988; <br />                                               319:525&#226;&#8364;&#8220;532. [PubMed: 2841597] <br />                                           Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva  James L, Catino JJ, Bishop WR, Pai JK. <br />                                               K- N-Ras geranylgeranylated cells treated farnesyl protein transferase inhibitors. J <br />                                               Biol Chem. 1997; 272:14459&#226;&#8364;&#8220;14464. [PubMed: 9162087] <br />                                           Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini  Khoury <br />                                               DS, et al. pivotal role endogenous TGF-beta-activated kinase-1 LKB1/AMP-activated <br />                                               protein kinase energy-sensor pathway. Proc Natl Acad Sci U S  2006; 103:17378&#226;&#8364;&#8220;17383. <br />                                               [PubMed: 17085580] <br />                                           Zou H, Wieser R, Massague J, Niswander L. Distinct roles type bone morphogenetic protein <br />                                               receptors formation differentiation cartilage. Genes Dev. 1997; 11:2191&#226;&#8364;&#8220;2203. <br />                                               [PubMed: 9303535] <br />  <br />  <br />  <br />                                                    Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                  Page 13 <br />  <br />  <br />                                                                            Research Highlights <br />                                           &#226;&#8364;&#162;    TAK1 kinase promotes survival KRAS-dependent colon cancer cells. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           &#226;&#8364;&#162;    TAK1 dependency correlates KRAS-mediated activation Wnt signaling. <br />                                           &#226;&#8364;&#162;    KRAS activates Wnt signaling TAK1 APC-deficient cancer cells. <br />                                           &#226;&#8364;&#162;    KRAS upregulates BMP signaling leading increased TAK1 kinase activity. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                          Page 14 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 1. Classification KRAS mutant colon cancer cells KRAS-independent KRAS- <br />                                           dependent groups <br />                                             Representative 6-day 96 viability assays 4 KRAS mutant colon cancer cell lines <br />                                           transduced control 2 independent KRAS-directed lentiviral shRNAs                                            B), 2 viral MOIs. Cell lines red text KRAS-independent, green text                                           KRAS-dependent. Quantitation transformation relative cell density values yields                                           Ras Dependency Index depicted Fig. 1B. <br />                                           (B) Ras Dependency Index plot panel 21 KRAS mutant colon cancer cell lines. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Dashed line represents &#226;&#8364;&#339;Dependency Threshold&#226;&#8364;? 2.0. Data presented mean <br />                                           independent experiments +/- SEM. <br />                                           (C) KRAS protein depletion 4 days post-infection KRAS-directed shRNAs effects <br />                                           apoptosis, assessed caspase-3 PARP cleavage, representative panel                                           KRAS-dependent versus-KRAS independent cell lines. Lanes 1, 2 3 panel  <br />                                           Data representative independent experiments. <br />                                           (D) Activating phosphorylations Erk (p-Erk1/2) Akt (p-Akt) kinases, following <br />                                           KRAS depletion SW837 KRAS-independent versus SW620 2 KRAS-dependent cells, 4 <br />                                           days post-infection 3 different viral titres (MOIs 1, 2 4) shKRAS-B. Total <br />                                           protein levels (t-Erk1 t-Akt) shown gel loading controls. Note: different <br />                                           exposure times used individual panels. Data representative                                           independent experiments. <br />  <br />  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                           Page 15 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 2. Analysis kinases &#226;&#8364;&#339;KRAS dependency signature&#226;&#8364;? colon cancer cell lines <br />                                             Schematic representation methodology used derive colon cancer KRAS <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           dependency gene expression data set. Gene expression microarray data 4 indicated <br />                                           KRAS-independent versus KRAS-dependent cell lines analyzed significantly <br />                                           underexpressed (IND) overexpressed (DEP) genes student T-test analysis  tailed, <br />                                           homoscedastic) followed selection probe sets average expression 2-fold <br />                                           higher lower, yielding 687 IND genes 832 DEP genes. <br />                                           (B) Hierarchical clustering gene expression 47 DEP &#226;&#8364;&#339;druggable&#226;&#8364;? protein, lipid                                           <span id='am-15' about='obo:IMR_0001351' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-16' property="oboInOwl:id" content="IMR:0001351" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:hasDbXref" content="KEGG:C00002" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:hasAlternativeId" content="IMR:0100127" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasExactSynonym" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasAlternativeId" content="IMR:0200394" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-24' property="rdfs:label" content="ATP" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:hasExactSynonym" content="adenosine triphosphate" datatype="xsd:string"></span>ATP</span>-dependent kinase genes kinase regulatory genes. Heat map shows log2 <br />                                           median-centered intensity values similarly expressed genes clustered using <br />                                           Euclidean distance similarity metric. MAP3K7 (encoding TAK1) highlighted                                           asterisk. <br />                                           (C) Protein expression levels indicated kinases panel KRAS-independent                                           KRAS-dependent cell lines. GAPDH serves loading control. <br />  <br />  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                            Page 16 <br />  <br />  <br />                                           (D) Depletion DEP kinase genes SW620 versus SW837 cells. colored bar <br />                                           represents individual shRNA sequence gene, color-coding Figure <br />                                           S1F. Fold growth inhibition shRNA kinase computed dividing relative <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           cell density SW837 SW620 cells using weighted average account                                           viral titre. plot shows cumulative log2 fold growth inhibition shRNA                                           kinase; e., value 1 plot indicates 2-fold greater growth inhibitory effect                                           given shRNA SW620 compared SW837 cells. log2 fold growth inhibition                                           individual shRNA cumulated kinase gene. Data represented                                           mean value corresponding shRNA independent experiments. <br />                                           (E) Knockdown TAK1 increasing viral titres shTAK1-D encoding lentiviruses <br />                                           (MOI) associated apoptotic effects assessed PARP cleavage. GAPDH serves                                           loading control. Data representative independent experiments. <br />                                           Figure S1 Table S1. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                       Page 17 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 3. Validation MAP3K7/TAK1 pro-survival mediator KRAS-dependent colon <br />                                           cancers <br />                                             IC50 values (&#206;&#188;M) effects cellular proliferation viability TAK1 <br />                                           kinase inhibitor 5Z-7-oxozeaenol panel colon cancer cell lines NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           genotyped KRAS mutant (KRAS-independent &#226;&#8364;&#8220; red circles KRAS-dependent &#226;&#8364;&#8220; green <br />                                           squares), BRAF mutant (blue triangles) wild-type KRAS BRAF  &#226;&#8364;&#8220; <br />                                           grey diamonds). Effects growth measured 3 days post-treatment. Data                                           represented mean 3 independent experiments error bars indicate median &#194;&#177; <br />                                           interquartile range. *denotes p&lt;0.00001; n.s. &#226;&#8364;&#8220; significant. <br />                                           (B) Effects TAK1 inhibition apoptosis signaling representative panel                                           KRAS-independent KRAS-dependent cell lines, 24h treatment. PARP                                           caspase-3 cleavage shown indicators apoptosis, AMPK threonine 172 (T172) <br />                                           phosphorylation shown downstream indicator TAK1 signaling activity. GAPDH <br />                                           serves gel loading control. <br />                                           (C) TAK1 inhibition mice xenografted human tumors derived HCT8/ <br />                                           SW837 (KRAS-independent) SK 1/SW620 (KRAS-dependent) cell lines. Cells <br />                                           expressing firefly luciferase injected subcutaneously flanks nude mice. <br />                                           Tumors shown imaged IVIS detection luminescence counts  photons/sec) <br />  <br />  <br />                                                  Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                     Page 18 <br />  <br />  <br />                                           following 14 days tumor growth followed 6 days treatment 15mg/kg <br />                                           5z-7-oxozeaenol vehicle (5% DMSO arachis oil), IP delivery q.d. Quantitation                                           tumor volume (mm3) shown. Tumor volume data represented mean 4 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           tumors 2 mice group +/- SEM. <br />                                           Figure S2 Table S2. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                       Page 19 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 4. Associations KRAS dependency gene set, TAK1 dependence KRAS- <br />                                           driven canonical Wnt signaling colon cancer patients <br />                                             Heat map representation gene expression correlated TAK1 dependence <br />                                           KRAS dependency gene set panel colon cancer cell lines various <br />                                           genotypes. Cell lines ordered IC50 values 5Z-7-oxozeaenol, leftmost                                           highest rightmost lowest. Clustering genes performed Euclidean <br />                                           distance similarity metric. Values presented log2 median-centered intensities. <br />                                           Genes highlighted orange text putative bona fide TCF4 target genes. <br />                                           (B) Basal normalized TCF4 luciferase reporter activity  FLASH) nominal units                                           panel KRAS-independent KRAS-dependent colon cancer cell lines. Data                                           represented means 3 independent experiments +/- SEM. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           (C) Average expression non-TCF4 TCF4 target genes depicted Figure 4A colon <br />                                           cancer patients genotyped APC mutant/KRAS-wild-type (red circles) APC <br />                                           mutant plus KRAS mutant (green squares). P-values represent comparison mean <br />                                           expression scores genes class. <br />                                           Figure S3. <br />  <br />  <br />  <br />  <br />                                                  Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                          Page 20 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 5. KRAS TAK1 regulate canonical Wnt signaling KRAS-dependent cancer cells <br />                                             FLASH luciferase reporter activity function lentiviral shRNA-mediated <br />                                           KRAS depletion increasing MOIs LS174T/SW1463 (KRAS-independent) versus <br />                                           SW620/SK 1 (KRAS-dependent) cells. Cell lines transduced stably express <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           luciferase control TCF4 response elements. Reporter activity plotted relative <br />                                           shGFP (vector) expressing cells. Data represented mean triplicate <br />                                           experiments +/- SEM. <br />                                           (B) FLASH activity KRAS-independent KRAS-dependent cell lines following <br />                                           TAK1 inhibition increasing concentrations 5Z-7-oxo (&#206;&#188;M). Data represented                                           means triplicate experiments &#194;&#177; SEM. <br />                                           (C) Protein expression levels endogenous Wnt target gene Axin 2 following treatment <br />                                           cells indicated concentrations 5Z-7-oxo. GAPDH serves loading control. <br />                                           (D) Laser confocal micrographs SW1116 KRAS-dependent cells treated                                           DMSO vehicle 5&#206;&#188;M 5Z-7-oxo 24h. E-cadherin localization shown red <br />                                           channel, &#206;&#178;-catenin green DAPI-stained nuclei blue. Scale bar = 20&#206;&#188;M. <br />                                           (E) Forced overexpression epitope-tagged oncogenic G12V mutated RAS protein <br />                                           isoforms HT29 cells sensitivity TAK1 pharmacological inhibition 5Z-7- <br />                                           oxozeaenol. Expression levels exogenous endogenous Ras proteins shown  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                     Page 21 <br />  <br />  <br />                                           immunoblotting pan-ras monoclonal antibody. NRAS/KRAS4B HA-tagged                                           KRAS4A V5-tagged. <br />                                           (F) Overexpression mutant KRAS(12V) followed TAK1 inhibition HT29 cells NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           effects FLASH reporter activity. Data presented means                                           independent experiments +/- SEM. <br />                                           (G) Overexpression KRAS(12V) HT29 cells effects TAK1 Erk <br />                                           phosphorylation (p-TAK1/p-Erk) Axin 2 levels. Total TAK1 Erk1 serve                                           loading controls. <br />                                           (H) Confocal micrographs showing E-cadherin KRAS (red) &#206;&#178;-catenin (green) <br />                                           localization vector control oncogenic HA tagged KRAS-4B(12V) expressing HT29 <br />                                           cells. KRAS expression visualized using HA polyclonal antibody. Scale bar = 25&#206;&#188;m. <br />                                           Figure S4. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                          Page 22 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 6. Oncogenic KRAS regulates BMP-7/BMPR1A signaling <br />                                             Depletion KRAS KRAS-independent (LS-174T SW837) KRAS- <br />                                           dependent cell lines (SW620 SK 1) subsequent effects expression BMP-7 <br />                                           downstream effects Smad1/TAK1 phosphorylation (p-Smad1/p-TAK1).                                           20kD secreted form BMP7 shown. Phospho-TAK1 represents TAK1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           autophosphorylation site measure TAK1 activity. Total Smad1/5/8 total <br />                                           TAK1 (t-Smad1/5/8/t-TAK1) proteins shown gel loading controls. Data                                           representative independent experiments. <br />                                           (B) Effects BMP7 depletion proliferation viability SW620 KRAS-dependent <br />                                           cells. Plot shows cell density 6 days post-infection shGFP control 5 different <br />                                           BMP7-directed lentiviral shRNAs. Data represented mean independent <br />                                           experiments &#194;&#177; SEM. Western blots right panel BMP-7 levels apoptotic <br />                                           effects measured PARP Caspase3 cleavage following BMP-7 depletion                                           independent lentiviral shRNAs (D E). <br />                                           (C) Effects BMP7 protein transcript levels following induced activation ER- <br />                                           KRAS(12V) fusion protein various doses 4-HT HT29 cells. Left panel shows <br />                                           levels total secreted BMP-7 following ER-KRAS(12V) induction 4-HT. Levels <br />  <br />  <br />  <br />  <br />                                                   Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                       Page 23 <br />  <br />  <br />                                           Axin 2 phosphorylated Erk (p-Erk1/2) shown following ER-KRAS(12V). <br />                                           Total Erk (t-Erk1) serves loading control. <br />                                           (D) FLASH reporter activity following 4-HT induced activation ER-KRAS(12V) <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           depletion indicated genes lentiviral shRNA delivery various viral titres. <br />                                           Reporter activity shown relative shGFP control. <br />                                           (E) Introduction V5-tagged constitutively activated (CA) mutant BMP receptor, <br />                                           BMPR1A (Q233D) control vector HT29 cells effects 5Z-7-oxozeaenol <br />                                           sensitivity terms IC50 values. <br />                                           (F) Signaling apoptotic effects TAK1 inhibition using 5Z-7-oxozeaenol                                           indicated concentrations 24h post-treatment BMPR1A-CA expressing cells. Caspase3                                           PARP cleavage indicators apoptotic cell death. Axin 2 levels shown readout <br />                                           Wnt signaling. Phosphorylated smad1/5/8 levels serve readout BMP signaling. <br />                                           GAPDH serves gel loading control. BMPR1A-CA expression visualized using                                           monoclonal V5 antibody. <br />                                           (G) Effects BMPR1A-CA expression &#206;&#178;-catenin localization (red) HT-29 cells <br />                                           following treatment 5&#206;&#188;M 5Z-7-oxozeaenol vehicle control 24h, assessed                                           immunofluorescence confocal microscopy. DAPI-stained nuclei shown blue. Scale <br />                                           bar = 10&#206;&#188;M. <br />                                           Figure S5. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Cell. Author manuscript; available PMC 2012 August 17. <br />                             Singh et al.                                                                                         Page 24 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           Figure 7. model context specific KRAS dependency colon cancers <br />                                           KRAS-independent colon cancers, APC loss function results hyperactivation                                           canonical Wnt signaling stabilization &#206;&#178;-catenin cooperation upstream <br />                                           Wnt activators. TAK1 negative regulator canonical Wnt signaling cells. <br />                                           KRAS-dependent cells, oncogenic KRAS upregulates BMP-7 expression/secretion, <br />                                           activating BMP receptor <br /> </body></html>